KR20220024821A - 악성 종양의 치료 방법 - Google Patents

악성 종양의 치료 방법 Download PDF

Info

Publication number
KR20220024821A
KR20220024821A KR1020227002122A KR20227002122A KR20220024821A KR 20220024821 A KR20220024821 A KR 20220024821A KR 1020227002122 A KR1020227002122 A KR 1020227002122A KR 20227002122 A KR20227002122 A KR 20227002122A KR 20220024821 A KR20220024821 A KR 20220024821A
Authority
KR
South Korea
Prior art keywords
day
phenyl
salt
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227002122A
Other languages
English (en)
Korean (ko)
Inventor
가즈오 고바
도시야스 시모무라
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20220024821A publication Critical patent/KR20220024821A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227002122A 2019-06-21 2020-06-19 악성 종양의 치료 방법 Withdrawn KR20220024821A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019115496 2019-06-21
JPJP-P-2019-115496 2019-06-21
PCT/JP2020/024113 WO2020256096A1 (ja) 2019-06-21 2020-06-19 悪性腫瘍の治療方法

Publications (1)

Publication Number Publication Date
KR20220024821A true KR20220024821A (ko) 2022-03-03

Family

ID=74040503

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002122A Withdrawn KR20220024821A (ko) 2019-06-21 2020-06-19 악성 종양의 치료 방법

Country Status (8)

Country Link
US (1) US20220354858A1 (https=)
EP (1) EP3988175A4 (https=)
JP (1) JP7574184B2 (https=)
KR (1) KR20220024821A (https=)
AU (1) AU2020297166A1 (https=)
MA (1) MA56549A (https=)
TW (1) TWI856115B (https=)
WO (1) WO2020256096A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137870A1 (ja) 2011-04-06 2012-10-11 大鵬薬品工業株式会社 新規イミダゾオキサジン化合物又はその塩
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
US20190350932A1 (en) 2016-03-04 2019-11-21 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2868660T3 (https=) * 2012-07-02 2018-05-26
JP6289459B2 (ja) 2013-06-20 2018-03-07 大鵬薬品工業株式会社 ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法
CN111943962A (zh) * 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co., Ltd. IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137870A1 (ja) 2011-04-06 2012-10-11 大鵬薬品工業株式会社 新規イミダゾオキサジン化合物又はその塩
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
US20190350932A1 (en) 2016-03-04 2019-11-21 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ann Oncol 2010; 21: p683-691
Cancer Res.2013; 73(Suppl 8): Abstract LB-197.
Cell 2007; 129, p1261-1274
Clin Cancer Res 2018, May1, 24(9): 2050-2059, (doi: 10.1158/1078-0432.CCR-17-2260)
J Clin Oncol. 2011; 29: 4688-4695.
학회 「EORTC-NCI-AACR 2017」의 포스터 발표 자료 "Characterization of TAS-117, a novel, highly potent and selective inhibitor of AKT"

Also Published As

Publication number Publication date
TW202114691A (zh) 2021-04-16
US20220354858A1 (en) 2022-11-10
JPWO2020256096A1 (https=) 2020-12-24
WO2020256096A1 (ja) 2020-12-24
MA56549A (fr) 2022-04-27
TWI856115B (zh) 2024-09-21
AU2020297166A1 (en) 2022-02-17
EP3988175A4 (en) 2023-06-28
JP7574184B2 (ja) 2024-10-28
EP3988175A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
JP6911019B2 (ja) Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
KR102793563B1 (ko) 악성 종양 치료용 제제 및 조성물
KR101673731B1 (ko) 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
KR20220024821A (ko) 악성 종양의 치료 방법
JP6757959B2 (ja) 抗がん剤
TWI530287B (zh) 組合療法
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
EP3053578B1 (en) Combination cancer therapy using azabicyclo compound
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
KR20130073948A (ko) 암 치료를 위한 새로운 병용 요법
CA2825790A1 (en) Combinations
KR102032933B1 (ko) 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물
RU2816126C2 (ru) Способ лечения злокачественной опухоли
WO2025041853A1 (ja) アザ二環式化合物と抗アンドロゲン剤を用いたがん併用療法
JP2019108385A (ja) がん治療
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202